Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo

International Journal of Oncology

Volumn 39, Issue 5, 2011, Pages 1123-1131

  Wang, Zhao Hong ^a   Chen, Hui ^a   Guo, Hong Chun ^a   Tong, Hong Fei ^a   Liu, Jin Xiang ^a   Wei, Wei Tian ^a   Tan, Wei ^a   Ni, Zhong Lin ^a   Liu, Hai Bin ^a   Lin, Sheng Zhang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Emodin; Gemcitabine; NF b; Pancreatic cancer; XIAP

Indexed keywords

ANTINEOPLASTIC AGENT; EMODIN; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DOWN-REGULATION; DRUG SYNERGISM; EMODIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; PANCREATIC NEOPLASMS; TUMOR BURDEN; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053198686     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1115     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Hidalgo M: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
4. Reni M, Cordio S, Milandri C, et al: Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 6: 369-376, 2005. (Pubitemid 40753742)
5. Wang XY, Li HJ, Wen H, Yan D and Peng SY: Influence of the adjuvant therapy on the survival of patients with stage II panc-reatic carcinoma. Front Med China 4: 430-435, 2010.
6. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J and Aggarwal BB: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67: 3853-3861, 2007. (Pubitemid 46762173)
7. Banerjee S, Kaseb AO, Wang Z, et al: Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 69: 5575-5583, 2009.
8. Basu S, Ghosh A and Hazra B: Evaluation of the antibacterial activity of Ventilago madraspatana Gaertn., Rubia cordifolia Linn. and Lantana camara Linn.: isolation of emodin and physcion as active antibacterial agents. Phytother Res 19: 888-894, 2005. (Pubitemid 41665959)
9. Li HL, Chen HL, Li H, et al: Regulatory effects of emodin on NF-kappaB activation and inflammatory cytokine expression in RAW 264.7 macrophages. Int J Mol Med 16: 41-47, 2005.
10. Lin SZ, Chen KJ, Tong HF, Jing H, Li H and Zheng SS: Emodin attenuates acute rejection of liver allografts by inhibiting hepatocellular apoptosis and modulating the Th1/Th2 balance in rats. Clin Exp Pharmacol Physiol 37: 790-794, 2010.
11. Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM and Lin YW: Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochem Pharmacol 79: 655-664, 2010.
12. Li J, Liu P, Mao H, Wanga A and Zhang X: Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro. Oncol Rep 21: 1605-1610, 2009.
13. Wang CG, Yang JQ, Liu BZ, et al: Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo. Eur J Pharmacol 627: 33-41, 2010.
14. Chen H, Wei W, Guo Y, et al: Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis. Oncol Rep 25: 1253-1261, 2011.
15. Huang Q, Shen HM, Shui G, Wenk MR and Ong CN: Emodin inhibits tumor cell adhesion through disruption of the membrane lipid Raft-associated integrin signaling pathway. Cancer Res 66: 5807-5815, 2006. (Pubitemid 43927135)
16. Muto A, Hori M, Sasaki Y, et al: Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther 6: 987-994, 2007. (Pubitemid 46554568)
17. Mitsiades N, Mitsiades CS, Poulaki V, et al: Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 99: 4079-4086, 2002. (Pubitemid 35332050)
18. Lee KB, Kim KR, Huh TL and Lee YM: Proton induces apop-tosis of hypoxic tumor cells by the p53-dependent and p38/JNK MAPK signaling pathways. Int J Oncol 33: 1247-1256, 2008.
19. Pratesi G, Petrangolini G, Tortoreto M, et al: Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res 65: 6388-6393, 2005. (Pubitemid 40994426)
20. Cha TL, Qiu L, Chen CT, Wen Y and Hung MC: Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res 65: 2287-2295, 2005. (Pubitemid 40490138)
21. Tang ZY, Wu YL, Gao SL and Shen HW: Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells. J Surg Res 145: 111-123, 2008.
22. Zhao C, Chen Z, Ye X, et al: Imaging a pancreatic carcinoma xenograft model with 11C-acetate: a comparison study with 18F-FDG. Nucl Med Commun 30: 971-977, 2009.
23. Niu J, Li Z, Peng B and Chiao PJ: Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. J Biol Chem 279: 16452-16462, 2004. (Pubitemid 38509343)
24. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR and Chiao PJ: The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127, 1999. (Pubitemid 29045184)
25. Vucic D and Fairbrother WJ: The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 13: 5995-6000, 2007. (Pubitemid 350075054)
26. Liu A, Chen H, Tong H, et al: Emodin potentiates the antitumor effects of gemcitabine in pancreatic cancer cells via inhibition of nuclear factor-kappaB. Mol Med Rep 4: 221-227, 2011.
27. Guo Q, Chen Y, Zhang B, Kang M, Xie Q and Wu Y: Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition. Biochem Pharmacol 77: 1674-1683, 2009.
28. Zou T, Rao JN, Guo X, et al: NF-kappaB-mediated IAP expression induces resistance of intestinal epithelial cells to apoptosis after polyamine depletion. Am J Physiol Cell Physiol 286: C1009-C1018, 2004. (Pubitemid 38506916)
29. Shrikhande SV, Kleeff J, Kayed H, et al: Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells. Anticancer Res 26: 3265-3273, 2006. (Pubitemid 44701495)
30. Deveraux QL, Roy N, Stennicke HR, et al: IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17: 2215-2223, 1998. (Pubitemid 28171907)